Investing in rapidly expanding biotech stocks can be a worthwhile long-term investment. Just one successful drug or device ...

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$1,319 Current share ...

Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase I for Adipocytic Sarcoma.

Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Zepbound® (tirzepatide) as the first and only prescription medicine for adults with moderate ...

Since pharmaceutical giant Eli Lilly (NYSE: LLY) reported earnings for the third quarter on Oct. 30, shares have been ...

Lupin Ltd acquires Huminsulin from Eli Lilly to expand diabetes portfolio, offering a range of human insulin options.